CapTemY90 for Grade 2 NET Liver Metastases


Study Number
646120
Phase
II
Age Group
Adult
Purpose

This is a Phase 2 evaluation of hepatic-progression free survival among patients with Grade 2 liver-dominant NET metastases undergoing combination therapy with CapTem and Y90 radioembolization.The hypothesis is to confirm safety and to assess if disease control is improved relative to expectation from either therapy alone.

Full Title

UPCC 04219: Phase 2 Study of Capecitabine-Temozolomide(CapTem) with yttrium-90 Radioembolization in the Treatment of Patients with Unresectable Metastatic Grade 2 Neuroendocrine Tumors

ClinicalTrials.Gov ID
NCT04339036

To inquire about participating in these studies, call 1-800-ROSWELL (1-800-767-9355) or e-mail askroswell@roswellpark.org.